NurExone Biologic Inc.

About NurExone Biologic Inc.

NurExone is a biotechnology company focused on developing exosome-based therapies for regenerative medicine. Their mission is to push the boundaries of medicine and biology with their ExoTherapy platform, aiming to regenerate, rewire, and recover damaged tissues, particularly for acute injuries like spinal cord injury.

Products & Services

ExoPTEN:A therapy for acute spinal cord injury using an siRNA sequence loaded onto exosomes. It has shown to regenerate and rewire neurons in lab animals, with 75% recovering motor function and bladder control after treatment. Received FDA Orphan Drug Designation in 2023, with first-in-human trials expected in 2025.

ExoTherapy Platform:A drug delivery platform based on exosomes, creating non-invasive nanodrugs by loading therapeutic compounds onto exosomes. It targets inflamed or damaged tissues, crosses the blood-brain barrier, and supports off-the-shelf targeted medicine for various indications.

Specialties

Exosome-based therapies Regenerative medicine Nanodrug delivery Spinal cord injury treatment Neuron regeneration

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 3185994 MR: - FA: C$3,185,994.43 FAN: 3185994	D: 2025-11-12 FD: 2025-11-12	-
2	RT: Private Placement T: - FT: Private Placement	A: 1200000 MR: - FA: C$1.2 Million FAN: 1200000	D: 2025-01-21 FD: 2025-01-21	-
3	RT: Non-brokered Private Placement T: - FT: Non-brokered Private Placement	A: 1737647 MR: - FA: $1,737,647.45 FAN: 1737647	D: 2024-11-01 FD: 2024-11-01	1 investors
4	RT: Private Placement T: - FT: Private Placement	A: 2000000 MR: - FA: up to $2,000,000 FAN: 2000000	D: 2024-09-26 FD: 2024-09-26	-
5	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 4000000 MR: - FA: C$4M FAN: 4000000	D: 2024-03-27 FD: 2024-03-27	-
6	RT: Private Placement T: - FT: Private Placement	A: 1489319 MR: - FA: CAD$1,985,758.04 FAN: 1489319	D: 2024-01-05 FD: 2024-01-05	-
7	RT: Grant T: - FT: Grant	A: 262500 MR: - FA: 1M NIS (~CAD$350K) FAN: 262500	D: 2023-10-11 FD: 2023-10-11	1 investors
8	RT: Private Placement T: - FT: Private Placement	A: 750000 MR: - FA: 750,000 to 1,400,000 CAD (minimum to maximum gross proceeds) FAN: 750000	D: 2023-08-09 FD: 2023-08-09	-

Warrant Exercise Latest

2025-11-12

$3.2M

Private Placement 2025-01-21

$1.2M

Non-brokered Private Placement 2024-11-01

$1.7M

View 7 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

Y

Yoram Drucker

VP Strategic Development & Chairman

LinkedIn (Pro only)

E

Eran Ovadya

Chief Financial Officer

LinkedIn (Pro only)

I

Ina Sarel

Head of CMC, Quality and Regulatory

LinkedIn (Pro only)

I

Inbar Paz-Benayoun

Head of Communications & Investor Relations

L

Lior Shaltiel

Chief Executive Officer & Director

L

Lyora Aharonov

R&D Director

View 35 more team members with Pro

Unlock Full Team Directory

Recent News